Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2007

View Archived Issues

PTC Therapeutics reports phase II trial data of PTC-124 for Duchenne muscular dystrophy

GenVec receives additional funding to develop novel adenovector-based HIV vaccines

Nventa reports update on phase I trial of new HspE-7 for cervical dysplasia

Two phase III studies show efficacy of asenapine in treating mania in bipolar I disorder

Preliminary PROTECT-1 results show efficacy of CCX-282-B in Crohn's disease

Barrier announces positive results from phase IIa study of pramiconazole in onychomycosis

Recent patents cover novel discoveries for the treatment of cancer

Approval obtained in Japan for additional pediatric indications for Claritin

Positive one-year results reported for fully bioabsorbable drug-eluting stent

New therapeutic agents for metabolic disorders reported in recent patents

EMEA supports use of rosiglitazone for type 2 diabetes

Recent Johns Hopkins patent imparts new nitroxyl (HNO) donors for cardiovascular disorders

Clinical trials add to evidence of adalimumab efficacy in Crohn's disease

Biogen Idec agents discussed at multiple sclerosis congress

Positive results reported for phase I FT-105 basal insulin trial

Tezampanel meets primary endpoint in phase IIb migraine trial

Xience V everolimus-eluting stent shows continued superiority to Taxus

Peregrine submits clinical protocol for new phase II bavituximab trial

Speedel discontinues SPP-200 development and focuses on SPP-301 and next-generation renin inhibitors

Tyrosinase DNA vaccines induce T-cell responses in melanoma patients

Genzyme acquires Bioenvision and gains rights to clofarabine

Orexigen's Contrave begins third phase III trial for treatment of obesity

Genzyme's Elaprase IV 6 mg launched in Japan

CHMP issues positive opinion of MabCampath in B-CLL therapy

Genzyme's Cholestagel launched in Europe

Noven receives FDA approvable letter for Stavzor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 10, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026